RVX Share Price

Open 2.29 Change Price %
High 2.29 1 Day -0.07 -3.07
Low 2.17 1 Week -0.20 -8.30
Close 2.21 1 Month 0.30 15.71
Volume 28220 1 Year 0.95 75.40
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 2.32
Resistance 1 2.28
Pivot 2.22
Support 1 2.14
Support 2 2.10
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 23.23 2.02%
MFC 23.23 2.02%
MFC 23.23 2.02%
MFC 23.23 2.02%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
CUM 0.90 13.92%
CUM 0.90 13.92%
DA-A 0.45 9.76%
HYD 0.37 8.82%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
MM 0.06 -14.29%
MM 0.06 -14.29%
ANX 0.07 -12.50%
ANX 0.07 -12.50%
CTU-A 0.19 -9.52%
BX 0.84 -8.70%
BX 0.84 -8.70%
TLB 3.88 -7.84%
TLB 3.88 -7.84%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 4
As on 23rd Mar 2017 RVX Share Price closed @ 2.21 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.62 & Buy for SHORT-TERM with Stoploss of 1.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for March
1st Target up-side 2.16
2nd Target up-side 2.26
3rd Target up-side 2.36
1st Target down-side 1.88
2nd Target down-side 1.78
3rd Target down-side 1.68
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.